🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 8 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 07/05/2021 | 214,36 | 216,77 | 213,81 | 215,01 | +0,87% | 1,38% | 1.232.000 |
| 06/05/2021 | 212,25 | 213,58 | 211,06 | 213,16 | -0,33% | 1,19% | 1.184.100 |
| 05/05/2021 | 214,85 | 215,84 | 213,24 | 213,87 | -0,46% | 1,21% | 1.254.800 |
| 04/05/2021 | 217,54 | 217,54 | 211,76 | 214,85 | -1,42% | 2,66% | 1.772.600 |
| 03/05/2021 | 217,27 | 219,69 | 216,70 | 217,95 | -0,11% | 1,38% | 1.367.000 |
| 30/04/2021 | 213,34 | 221,41 | 213,00 | 218,20 | +2,99% | 3,94% | 2.592.700 |
| 29/04/2021 | 213,60 | 213,80 | 210,27 | 211,86 | -0,76% | 1,65% | 1.656.000 |
| 28/04/2021 | 215,68 | 215,72 | 212,81 | 213,48 | -0,95% | 1,35% | 1.426.800 |
| 27/04/2021 | 217,10 | 218,15 | 215,00 | 215,53 | -0,66% | 1,45% | 1.223.900 |
| 26/04/2021 | 217,74 | 218,28 | 214,46 | 216,97 | -0,43% | 1,75% | 1.303.400 |
| 23/04/2021 | 217,07 | 218,81 | 215,77 | 217,90 | +0,89% | 1,40% | 1.205.100 |
| 22/04/2021 | 217,11 | 218,93 | 214,00 | 215,98 | -1,72% | 2,27% | 1.777.600 |
| 21/04/2021 | 220,79 | 221,48 | 217,82 | 219,76 | -0,18% | 1,66% | 1.173.400 |
| 20/04/2021 | 218,84 | 222,00 | 218,15 | 220,16 | +0,45% | 1,76% | 1.370.500 |
| 19/04/2021 | 220,86 | 222,59 | 218,15 | 219,18 | -0,10% | 2,01% | 1.510.900 |
| 16/04/2021 | 222,34 | 222,78 | 219,24 | 219,39 | -0,77% | 1,59% | 1.917.500 |
| 15/04/2021 | 218,52 | 222,35 | 218,00 | 221,10 | +1,83% | 1,99% | 1.686.500 |
| 14/04/2021 | 216,16 | 220,25 | 216,16 | 217,13 | +0,55% | 1,89% | 1.564.700 |
| 13/04/2021 | 214,61 | 218,70 | 214,46 | 215,94 | +1,10% | 1,98% | 1.628.700 |
| 12/04/2021 | 212,68 | 214,45 | 211,21 | 213,60 | +0,12% | 1,52% | 1.468.000 |
| 09/04/2021 | 210,50 | 213,82 | 209,53 | 213,35 | +1,46% | 2,04% | 1.533.600 |
| 08/04/2021 | 214,18 | 216,05 | 209,95 | 210,28 | -1,15% | 2,85% | 2.259.400 |
| 07/04/2021 | 215,71 | 218,47 | 211,70 | 212,72 | -1,20% | 3,14% | 1.515.400 |
| 06/04/2021 | 215,50 | 216,46 | 213,15 | 215,30 | -0,01% | 1,54% | 1.926.000 |
| 05/04/2021 | 214,38 | 215,61 | 213,18 | 215,32 | +1,07% | 1,13% | 2.050.000 |
| 01/04/2021 | 215,89 | 216,02 | 212,30 | 213,04 | -0,86% | 1,72% | 2.071.400 |
| 31/03/2021 | 213,38 | 216,06 | 212,87 | 214,89 | +0,89% | 1,49% | 1.523.300 |
| 30/03/2021 | 214,75 | 215,50 | 212,37 | 212,99 | -1,72% | 1,46% | 1.272.500 |
| 29/03/2021 | 213,93 | 218,46 | 212,21 | 216,71 | +0,96% | 2,92% | 1.531.500 |
| 26/03/2021 | 212,50 | 214,96 | 209,22 | 214,64 | +1,07% | 2,70% | 2.848.400 |